Endothelial protein C receptor is overexpressed in rheumatoid arthritic (RA) synovium and mediates the anti-inflammatory effects of activated protein C in RA monocytes

Annals of the Rheumatic Diseases

Volumn 66, Issue 12, 2007, Pages 1574-1580

  Xue, Meilang ^a   March, Lyn ^a   Sambrook, Philip N ^a   Fukudome, Kenji ^b   Jackson, Christopher J ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; CHEMOATTRACTANT; CHLORDANE; ENDOTHELIAL PROTEIN C RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ISOLATION; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIUM; UPREGULATION;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANALYSIS OF VARIANCE; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; NF-KAPPA B; OSTEOARTHRITIS; PROTEIN C; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 36749017585     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.068239     Document Type: Article

References (40)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
2. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
3. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR. Macrophages in rheumatoid arthritis. Arthritis Res 2000;2:189-202.
4. Athanasou NA. Current concepts review - cellular biology of bone-resorbing cells. J Bone Joint Surg Am 1996;78:1096-112.
5. Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R. Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med 2004;2:6.
6. Cutolo M, Sulli A, Barone A, Seriolo B, Accardo S. Macrophages, synovial tissue and rheumatoid arthritis [review]. Clin Exp Rheum 1993;11:331-9.
7. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein c activated protein c receptor. J Biol Chem 1994;269:26486-91.
8. Xue M, Campbell D, Sambrook PN, Fukudome K, Jackson CJ. Endothelial protein C receptor and protease-activated receptor-1 mediate induction of a wound-healing phenotype in human keratinocytes by activated protein C. J Invest Dermatol 2005;125:1279-85.
9. Galligan L, Livingstone W, Volkov Y, Hokamp K, Murphy C, Lawler M, et al. Characterization of protein C receptor expression in monocytes. Br J Haematol 2001;115:408-14.
10. Esmon CT. The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway. J Autoimmun 2000;15:113-6.
11. Esmon CT. Crosstalk between inflammation and thrombosis. Maturitas 2004;47:305-14.
12. Taylor FBJ, Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000;95:1680-6.
13. Iwaki T, Cruz DT, Martin JA, Castellino FJ. A cardioprotective role for the endothelial protein C receptor in lipopolysaccharide-induced endotoxemia in the mouse. Blood 2005;105:2364-71.
14. Li W, Zheng X, Gu J, Hunter J, Ferrell GL, Lupu F, et al. Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost 2005;3:1351-9.
15. Crawley JT, Gu JM, Ferrell G, Esmon CT. Distribution of endothelial cell protein C/activated protein C receptor (EPCR) during mouse embryo development. Thromb Haemost 2002;88:259-66.
16. Gu JM, Crawley JT, Ferrell G, Zhang F, Li W, Esmon NL, et al. Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J Biol Chem 2002;277:43335-43.
17. Li W, Zheng X, Gu JM, Ferrell GL, Brady M, Esmon NL, et al. Extraembryonic expression of EPCR is essential for embryonic viability. Blood 2005;106:2716-22.
18. Buisson-Legendre N, Smith S, March L, Jackson C. Elevation of activated protein C in synovial joints in rheumatoid arthritis and its correlation with matrix metalloproteinase 2. Arthritis Rheum 2004;50:2151-6.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, C. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
20. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
21. Thakur A, Willcox MD. Contact lens wear alters the production of certain inflammatory mediators in tears. Exp Eye Res 2000;70:255- 9.
22. Makarov SS. NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 2001;3:200-6.
23. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997;17:4015-23.
24. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994;179:1895-902.
25. Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-celláactivation. PNAS 1996;93:7849-54.
26. Oganesyan V, Oganesyan N, Terzyan S, Qu D, Dauter Z, Esmon NL, et al. The crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem 2002;277:24851-4.
27. Hong S, Scherer DC, Singh N, Mendiratta SK, Serizawa I, Koezuka Y, et al. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice. Immunol Rev 1999;169:31-44.
28. Moody DB, Besra GS, Wilson IA, Porcelli SA. The molecular basis of CD1-mediated presentation of lipid antigens. Immunol Rev 1999;172:285-96.
29. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 1997;186:131-7.
30. Stephenson DA, Toltl U, Beaudin S, Liaw PC. Modulation of monocyte function by activated protein C, a natural anticoagulant. J Immunol 2006;177:2115-22.
31. Brueckmann M, Hoffmann U, Dvortsak E, Lang S, Kaden JJ, Borggrefe M, et al. Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis. Inflamm Res 2004;53:528-33.
32. Yuksel M, Okajima K, Uchiba M, Horiuchi S, Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 2002;88:267-73.
33. Schmidt-Supprian M, Murphy C, While B, Lawler M, Kapurniotu A, Voelter W, et al. Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes. Eur Cytokine Netw 2000;11:407-13.
34. Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996;39:115-24.
35. Miyazawa K, Mori A, Yamamoto K, Okudaira H. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-kappaB and CBF1. Am J Pathol 1998;152:793-803.
36. Campbell IK, Gerondakis S, O'Donnell K, Wicks IP. Distinct roles for the NF-[kappa]B1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 2000;105:1799-806.
37. Bondeson J. The mechanisms of action of disease-modifying antirheumatic drugs: A review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Gen Pharmacol Vasc Syst 1997;29:127-50.
38. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
39. Leech M, Lacey D, Xue JR, Santos L, Hutchinson P, Wolvetang E, et al. Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum 2003;48:1881-9.
40. Mikulowska A, Metz CN, Bucala R, Holmdahl R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol 1997;158:5514-7.